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BACKGROUND: Antiplatelet therapy increases the risk of hematoma expansion in intracerebral hemorrhage (ICH) while the effect 
on functional outcome is uncertain.
METHODS AND RESULTS: This is an exploratory analysis of the TICH- 2 (Tranexamic Acid in Intracerebral Hemorrhage- 2) double- blind, 
randomized, placebo- controlled trial, which studied the efficacy of tranexamic acid in patients with spontaneous ICH within 8 hours 
of onset. Multivariable logistic regression and ordinal regression were performed to explore the relationship between pre- ICH an-
tiplatelet therapy, and 24- hour hematoma expansion and day 90 modified Rankin Scale score, as well as the effect of tranexamic 
acid. Of 2325 patients, 611 (26.3%) had pre- ICH antiplatelet therapy. They were older (mean age, 75.7 versus 66.5 years), more likely 
to have ischemic heart disease (25.4% versus 2.7%), ischemic stroke (36.2% versus 6.3%), intraventricular hemorrhage (40.2% ver-
sus 27.5%), and larger baseline hematoma volume (mean, 28.1 versus 22.6 mL) than the no- antiplatelet group. Pre- ICH antiplatelet 
therapy was associated with a significantly increased risk of hematoma expansion (adjusted odds ratio [OR], 1.28; 95% CI, 1.01– 
1.63), a shift toward unfavorable outcome in modified Rankin Scale (adjusted common OR, 1.58; 95% CI, 1.32– 1.91) and a higher 
risk of death at day 90 (adjusted OR, 1.63; 95% CI, 1.25– 2.11). Tranexamic acid reduced the risk of hematoma expansion in the 
overall patients with ICH (adjusted OR, 0.76; 95% CI, 0.62– 0.93) and antiplatelet subgroup (adjusted OR, 0.61; 95% CI, 0.41– 0.91) 
with no significant interaction between pre- ICH antiplatelet therapy and tranexamic acid (P interaction=0.248).
CONCLUSIONS: Antiplatelet therapy is independently associated with hematoma expansion and unfavorable functional out-
come. Tranexamic acid reduced hematoma expansion regardless of prior antiplatelet therapy use.
REGISTRATION: URL: https://www.isrctn.com; Unique identifier: ISRCTN93732214.
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Approximately 25% of patients with intracerebral hemorrhage (ICH) are on antiplatelet treatment before ICH.1 Antiplatelet therapy impairs hemo-
stasis, which may lead to hematoma expansion.2 In 
addition, patients taking antiplatelet therapy were more 
likely to have a previous ischemic stroke, ischemic 
heart disease, or peripheral vascular disease leading to 
more post- ICH complications. Nevertheless, the effect 
of antiplatelet therapy on clinical outcomes is uncer-
tain. Some studies reported that pre- ICH antiplatelet 
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therapy increased the risk of neurological deterioration, 
death, and poor functional outcome,1,3– 5 while others 
did not.1,6– 10 Antiplatelet therapy was reported to be 
associated with larger baseline hematoma volume,6 
intraventricular hemorrhage,11 and hematoma expan-
sion2,12 in some studies, though others have shown 
that antiplatelet therapy did not have significant effects 
on hematoma characteristics.9,10 A large individual 
patient data meta- analysis (5435 patients, 36 obser-
vational cohorts) concluded that antiplatelet therapy, 
as well as shorter time from onset to imaging, larger 
baseline hematoma volume, and pre- ICH anticoagu-
lant therapy, independently increased the risk of hema-
toma expansion.2
There is currently no specific hemostatic therapy 
for antiplatelet- associated intracerebral hemorrhage. 
Platelet transfusion was harmful in 1 randomized 
controlled trial.13 The effects of tranexamic acid on 
antiplatelet- associated ICH have not been studied in a 
randomized controlled setting.
In the primary publication of the TICH- 2 (Tranexamic 
Acid in Intracerebral Hemorrhage- 2) trial, there was no 
significant difference in the primary outcome of or-
dinal shift in day 90 modified Rankin scale between 
tranexamic acid and placebo arm, despite a reduction 
in hematoma expansion.14 In the current analysis, we 
aimed to explore the relationship between pre- ICH an-
tiplatelet therapy and hematoma characteristics and 
functional outcome in spontaneous ICH; and to ex-
plore the effect of tranexamic acid in patients taking 
antiplatelet therapy. We hypothesized that antiplatelet 
therapy increases the risk of hematoma expansion and 
poor functional outcome and that tranexamic acid has 
a beneficial effect on hematoma expansion and out-
come in patients taking antiplatelet therapy.
METHODS
Data Sharing
The trial data can be shared upon reasonable re-
quest to the corresponding author and trial steering 
committee.
Study Design and Population
We analyzed data from the TICH- 2 trial, which was 
a prospective multicenter randomized double- blind 
placebo- controlled trial. Patients aged >18 years with 
spontaneous ICH presenting within 8 hours of symp-
toms onset were eligible, while secondary (macro-
vascular or structural) causes of ICH were excluded. 
Patients who were taking anticoagulants at the time 
of ICH were excluded as well. Recruited patients 
were randomized 1:1 with minimization on key prog-
nostic factors and stratification by country to receive 
2  g of intravenous tranexamic acid or matching pla-
cebo. Detailed descriptions of the trial were previously 
published.14– 16
Outcomes
We compared hematoma expansion at 24- hour, early 
outcomes (death and neurological deterioration within 
7 days), and day 90 outcomes (modified Rankin Scale, 
disability, cognition, depression, and quality- of- life 
scores) between the antiplatelet and no- antiplatelet 
groups. In the antiplatelet subgroup analysis, we ex-
plored the effects of tranexamic acid on hematoma 
characteristics and clinical outcomes. These outcomes 
were prespecified in the trial protocol.15
Definitions
Hematoma expansion was defined as an increase 
of >6  mL or >33% in hematoma volume at 24- hour 
computed tomography scan compared with baseline 
hematoma volume, measured using semiautomated 
segmentation technique with ITK- SNAP version 3.6.0 
software.17,18 Details on image acquisition and analy-
ses were previously described.19 A Modified Rankin 




• Prior antiplatelet therapy is associated with an 
increased risk of hematoma expansion, neu-
rological deterioration, death, and unfavorable 
functional outcome in spontaneous intracer-
ebral hemorrhage.
• Tranexamic acid reduced hematoma expansion 
but did not improve day 90 functional outcome 
in patients with intracerebral hemorrhage re-
gardless of prior antiplatelet therapy.
What Are the Clinical Implications?
• The use of tranexamic acid in patients with 
antiplatelet- associated intracerebral hemor-
rhage needs to be further studied.
Nonstandard Abbreviations and Acronyms
DASH Desmopressin for Reversal of 
Antiplatelet Drugs in Stroke Due to 
Hemorrhage
ICH intracerebral hemorrhage
TICH- 2 Tranexamic Acid in Intracerebral 
Hemorrhage- 2
J Am Heart Assoc. 2021;10:e019130. DOI: 10.1161/JAHA.120.019130 3
Law et al Antiplatelet- Associated Intracerebral Hemorrhage
Statistical Analysis
Descriptive analysis was performed using the 
Student t, Mann- Whitney U, and chi- squared tests. 
Multiple linear regression, multivariable binary logistic 
regression, and ordinal logistic regression analyses 
with adjustment of covariates (which are key prog-
nostic factors: age, sex, systolic blood pressure, 
National Institutes of Health Stroke Scale, onset to 
randomization time, intraventricular hemorrhage, and 
baseline hematoma volume, as well as country of re-
cruitment) were performed to determine the effect of 
antiplatelet therapy on outcomes and also the effect 
of tranexamic acid on outcomes in the antiplatelet 
subgroup. The selection of covariates was prespeci-
fied in our statistical analysis plan18 and were simi-
lar to the selection of covariates as reported in the 
main result paper.14 We report the odds ratio for ef-
fect of tranexamic acid for the antiplatelet and no- 
antiplatelet subgroups separately and also the P 
value for interaction between antiplatelet intake sta-
tus and tranexamic acid treatment. Statistical analy-
ses were performed using SPSS version 24 (IBM, 
Armonk, NY). A P value of <0.05 was considered 
statistically significant.
Ethics Approval
This study was approved by the national and institu-
tional ethics review committees of participating coun-
tries/centers. Written informed consent was obtained 
from the patient(s) or their representatives.
RESULTS
Of the 2325 patients recruited, 611 (26.3%) were tak-
ing antiplatelet therapy at the time of ICH, while 1713 
(73.7%) were not; information on antiplatelet intake was 
not available in 1 patient. Data on functional outcome 
and hematoma expansion were available in 2306 and 
2077 patients, respectively (Figure  S1). Patients who 
were taking antiplatelet therapy were significantly older, 
more likely to have previous stroke or ischemic heart 
disease, and had more severe stroke and lower sys-
tolic blood pressure on admission (Table  1). Patients 
with pre- ICH antiplatelet therapy had significantly 
larger baseline hematoma volume and were more likely 
to have intraventricular hemorrhage, subarachnoid ex-
tension, old infarct(s), leukoaraiosis, and cerebral atro-
phy on baseline computed tomography scan. There 
was no difference in the proportion of patients with su-
pratentorial lobar, supratentorial deep, and infratentorial 
hematoma between the antiplatelet and no- antiplatelet 
groups. Within the antiplatelet group, characteristics 
of patients who received tranexamic acid and placebo 
were similar (Table 1).
At 24 hours, patients with pre- ICH antiplatelet ther-
apy had significantly larger hematoma volume, greater 
absolute hematoma growth, and hematoma expan-
sion compared with the no- antiplatelet group (Table 2). 
The risks of intraventricular and subarachnoid exten-
sion of hemorrhage were significantly increased as 
well. The risks of neurological deterioration and death 
in the first 7 days were significantly higher in the an-
tiplatelet group even after adjusting for key prognos-
tic factors, as stated in the Methods section. At day 
90, the risks of death (adjusted odds ratio [aOR], 1.63; 
95% CI, 1.25– 2.11; P<0.001) and poor functional out-
come (aOR, 1.52; 95% CI, 1.17– 1.98; P=0.002) were 
significantly higher in the antiplatelet group compared 
with the no- antiplatelet group. Similarly, disability, de-
pression, quality of life, and cognition scores were sig-
nificantly worse in the antiplatelet group (Table 2). The 
proportion of patients with new stroke, acute coronary 
syndrome, and venous thromboembolism did not dif-
fer between the 2 groups. Pre- ICH antiplatelet therapy 
was associated with a significant shift toward unfavor-
able outcome in ordinal regression analysis (aOR, 1.58; 
95% CI, 1.32– 1.91; P<0.001; Figure 1).
We explored the effect of tranexamic acid on outcomes 
in the antiplatelet group. Tranexamic acid significantly 
reduced hematoma expansion (aOR, 0.61; 95% CI, 
0.41– 0.91; P=0.015) but did not have significant effects 
on all clinical outcomes (Table  3). Tranexamic acid 
did not have a significant benefit on shift of modified 
Rankin Scale at day 90 (aOR, 0.92; 95% CI, 0.68– 1.25; 
P=0.589; ordinal regression analysis with adjustment 
for age, sex, systolic blood pressure, National Institutes 
of Health Stroke Scale, onset to randomization time, 
intraventricular hemorrhage, and country; Figure S2).
We examined the effect of tranexamic acid on he-
matoma expansion, death, and modified Rankin Scale 
>3 at day 90 stratified by pre- ICH antiplatelet versus 
no antiplatelet. Overall, tranexamic acid significantly 
reduced the risk of hematoma expansion but not 
death and dependency. Tranexamic acid significantly 
reduced hematoma expansion in the antiplatelet sub-
group (aOR, 0.61; 95% CI, 0.41– 0.91) but not in the no- 
antiplatelet subgroup (aOR, 0.81; 95% CI, 0.64– 1.03), 
though there was no significant statistical interaction 
(P=0.248; Figure 2).
DISCUSSION
In this exploratory analysis of the TICH- 2 trial, pre- ICH 
antiplatelet therapy was associated with an increased 
risk of hematoma expansion, as well as intraventricular 
and subarachnoid extension of hemorrhage. This sug-
gests that antiplatelet therapy is associated with sig-
nificant impairment of hemostasis in ICH. However, the 
increased risk of bleeding may be attributed to other 
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confounders such as older age and leukoaraiosis, 
which were more common in patients taking antiplate-
let therapy.
Our findings are in agreement with a large individual 
patient data meta- analysis that included 5435 patients 
from 36 cohorts, which concluded pre- ICH antiplate-
let therapy as an independent predictor of hematoma 
expansion.2 On the other hand, several large studies 
found that pre- ICH antiplatelet therapy did not result in 
hematoma expansion.9,10 This may be because of the 
heterogenous population that antiplatelet- associated 
ICH represents or that the definition of hematoma 
expansion in terms of changes in volume or timing 
of follow- up neuroimaging was not standardized. For 
example, one study that did not find antiplatelet ther-
apy as significant risk factor for hematoma expansion 
used a cutoff of ≥12.5 mL as compared with >6 mL in 
our study.9
Pre- ICH antiplatelet therapy was associated with 
worse early outcome of neurological deterioration and 
death within 7 days, as well as death and functional 
outcome at 90  days. Several previous studies con-
cluded similarly,1,3– 5 while others disputed the effect 
of antiplatelet therapy on longer- term outcome.1,6– 10 
Worse functional outcome and death in patients tak-
ing antiplatelet therapy may be confounded by ad-
verse prognostic factors such as older age and higher 
prevalence of vascular disease.20 In this analysis, we 














Age, mean (SD), y 75.7 (11.3) 66.5 (13.8) 0.001 75.8 (11.3) 75.5 (11.3) 0.725
Sex, male 366 (59.9%) 934 (54.5%) 0.071 190 (60.1%) 176 (59.7%) 0.907
Onset to CT time, h, mean (SD) 2.4 (1.3) 2.2 (1.3) 0.002 2.5 (1.4) 2.4 (1.3) 0.407
Onset to randomization time, h, mean (SD) 4.1 (1.7) 3.9 (1.7) 0.022 4.1 (1.8) 4.0 (1.7) 0.563
Premorbid mRS, median (IQR) 0 (0– 2) 0 (0– 0) <0.001 0 (0– 2) 0 (0– 2) 0.480
Glasgow Coma scale, median (IQR) 14 (12– 15) 15 (12– 15) 0.002 14 (12– 15) 14 (12– 15) 0.592
NIHSS, median (IQR) 13 (7– 20) 12 (7– 18) 0.018 14 (6– 20) 13 (8– 20) 0.816
Admission SBP, mean (SD), mm Hg 171.3 (27.4) 176.0 (30.5) <0.001 171.2 (28.3) 171.5 (26.4) 0.912
24- h SBP, mean (SD), mm Hg* 149.1 (20.8) 149.4 (20.1) 0.743 147.8 (21.2) 150.4 (20.3) 0.144
Previous stroke or TIA 221 (36.2%) 108 (6.3%) 0.001 110 (35.4%) 111 (38.1%) 0.480
Previous intracerebral hemorrhage 27 (4.5%) 99 (5.8%) 0.210 14 (4.5%) 13 (4.4%) 0.983
Previous ischemic heart disease 155 (25.4%) 47 (2.7%) 0.001 84 (27.2%) 71 (24.3%) 0.422
Treatment with tranexamic acid 316 (51.7%) 844 (49.3%) 0.299 … …
Country (United Kingdom) 518 (84.8%) 1391 (81.2%) 0.048 266 (84.2%) 252 (85.4%) 0.668
On antiplatelet therapy, day 7 10 (1.7%) 2 (0.1%) <0.001 2 (0.6%) 8 (2.7%) 0.046
On antiplatelet therapy, day 90 31 (9.6%) 29 (2.4%) <0.001 20 (12.4%) 11 (6.8%) 0.089
Radiological (CT scan)
Location
Supratentorial lobar 189 (31.7%) 499 (29.6%) 0.329 98 (31.7%) 91 (31.7%) 0.998
Supratentorial deep 369 (61.9%) 1082 (64.1%) 0.332 176 (61.3%) 193 (62.5%) 0.775
Infratentorial 38 (6.4%) 106 (6.3%) 0.936 20 (7.0%) 18 (5.8%) 0.568
Baseline hematoma volume, mean  
(SD), mL
28.1 (31.5) 22.6 (25.3) <0.001 29.9 (33.7) 26.1 (28.9) 0.134
Intraventricular hemorrhage 241 (40.2%) 466 (27.5%) <0.001 131 (42.3) 110 (38.1) 0.295
Subarachnoid hemorrhage 95 (15.5%) 204 (11.9%) 0.023 52 (16.8) 43 (14.9) 0.515
Old infarct(s) 438 (72.8%) 955 (56.4%) <0.001 223 (71.5) 215 (74.1) 0.463
Leukoaraiosis 350 (58.1%) 707 (41.7%) <0.001 184 (59.0) 166 (57.2) 0.667
Cerebral atrophy 584 (97.0%) 1515 (89.4%) <0.001 304 (97.4) 280 (96.6) 0.524
Analyses by chi- square, Student t test, or Mann- Whitney U test. CT indicates computed tomography; IQR, interquartile range; mRS, modified Rankin Scale; 
NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; and TIA, transient ischemic attack.
*No data available on SBP between admission and 24 hours.
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included key prognostic factors as covariates in the 
regression analyses, accounting for possible base-
line confounders such as age and National Institutes 
of Health Stroke Scale. In addition, pre- ICH anti-
platelet therapy was associated with worse day 90 
Barthel Index, cognitive, depression, and quality- of- 
life scores. The negative effect of antiplatelet therapy 
in ICH is likely related to a larger baseline hematoma 
and increased risk of hematoma expansion in the 
antiplatelet group. These findings highlight the need 
to prioritize research and clinical care in antiplatelet- 
associated ICH. An example of clinical trials that spe-
cifically targets antiplatelet- associated ICH is the DASH 
(Desmopressin for Reversal of Antiplatelet Drugs in 
Stroke Due to Hemorrhage) trial that involved the use 
of desmopressin in these patients (NCT03696121).21
Another important finding is that there was no het-
erogeneity of hemostatic effect of tranexamic acid 
across the antiplatelet and no- antiplatelet subgroups. 
In fact, the reduction in aOR for hematoma expansion 
was numerically greater in the antiplatelet subgroup 
(aOR, 0.61; 95% CI, 0.41– 0.91) compared with the 
no- antiplatelet subgroup (aOR, 0.81, 95% CI 0.64– 
1.03). The absolute 24- hour hematoma volume reduc-
tion with tranexamic acid was greater as well in the 
antiplatelet subgroup (3.0 mL, Table 3) compared with 
the reduction in all patients (1.4 mL) as reported in the 
main publication.14 However, as the P for interaction 
was not significant (P=0.248), these findings do not 
support a greater benefit of tranexamic acid in the an-
tiplatelet subgroup compared with the no- antiplatelet 
subgroup.
We hypothesized that there are several mecha-
nisms of how tranexamic acid, an antifibrinolytic agent, 
may have exerted hemostatic effect in antiplatelet- 
associated ICH despite not having a direct platelet- 
enhancing effect. Antiplatelet therapy such as aspirin 
acts predominantly by inhibiting platelet aggregation, 
but it may also inhibit acetylate lysine residues in fi-
brinogen leading to increased fibrin clot permeability 
and increased vulnerability to fibrinolysis,22,23 which 
may have an important role in hematoma expansion in 
ICH.24 Tranexamic acid acts by preventing the break-
down of stable fibrin clots. Therefore, it is possible that 
Table 2. Outcomes After Intracerebral Hemorrhage Associated With Versus Without Prior Antiplatelet Therapy
Outcomes Antiplatelet No Antiplatelet OR/MD (95% CI)* P Value
Radiological, 24- h CT
Hematoma volume, mean (SD), mL 33.8 (39.3) 24.8 (27.4) 9.0 (5.4, 12.6) <0.001
Hematoma growth, mean (SD), mL 7.3 (21.4) 3.3 (13.5) 3.2 (1.7, 4.8) <0.001
Hematoma expansion† 165 (30.7%) 403 (25.1%) 1.28 (1.01, 1.63) 0.046
New interventricular hemorrhage 53 (9.8%) 126 (7.8%) 1.58 (1.12, 2.24) 0.010
Subarachnoid extension‡ 47 (8.7%) 75 (4.7%) 1.99 (1.36, 2.91) <0.001
Day 7
Neurological deterioration§ 245 (40.1%) 402 (23.5%) 1.52 (1.21, 1.91) <0.001
Death 106 (17.3%) 118 (6.9%) 1.94 (1.40, 2.69) <0.001
DNAR 215 (35.2%) 294 (17.2%) 1.64 (1.25, 2.15) <0.001
Day 90
Death 212 (34.8%) 287 (16.9%) 1.63 (1.25, 2.11) <0.001
mRS >3 417 (68.4%) 841 (49.6%) 1.52 (1.17, 1.98) 0.002
Barthel Index, mean (SD) 37.5 (44.2) 58.7 (42.4) −6.5 (−9.7, −3.4) <0.001
EQ5D, mean (SD) 0.23 (0.37) 0.38 (0.40) −0.05 (−0.08, −0.02) 0.003
TICS- M, mean (SD) 7.5 (11.7) 16.0 (12.2) −2.2 (−3.3, −1.0) <0.001
ZDS, mean (SD) 81.7 (28.1) 62.3 (28.5) 6.3 (3.5, 9.1) <0.001
Safety events||
New stroke 4 (0.7%) 11 (0.6%) … 0.544
New acute coronary syndrome 1 (0.2%) 4 (0.2%) … 1.000
New venous thromboembolism 6 (1.6%) 25 (1.8%) … 1.000
DNAR indicates do not attempt resuscitation; EQ5D, Euro Quality of Life; MD, mean difference; mRS, modified Rankin Scale; NIHSS, National Institutes of 
Health Stroke Scale; OR, odds ratio; TICS- M, modified telephone interview cognitive status; and ZDS, Zung depression scale.
*Analyses are linear or binary logistic regression adjusted for age, sex, systolic blood pressure, NIHSS, onset to randomization time, intraventricular 
hemorrhage, treatment group and country, except for †hematoma expansion and ‡subarachnoid extension where baseline hematoma volume and presence 
of baseline subarachnoid hemorrhage were additional covariates respectively. The selection of variables was based on the main analyses, where minimization 
factor and stratification by country were prespecified covariates.
§Neurological deterioration: increase of NIHSS ≥4 or decrease in Glasgow Coma Scale score of ≥2.
||Fisher’s exact test.
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(n=316) Placebo (n=295) OR/MD (95% CI)* P Value
Baseline CT
Hematoma volume, mL, mean (SD) 29.9 (33.7) 26.1 (28.9) 3.8 (−1.2 to 8.9) 0.136
24- h CT
Hematoma volume, mL, mean (SD) 35.0 (40.1) 32.4 (38.4) 2.6 (−4.1 to 9.3) 0.442
Hematoma growth, mL, mean (SD) 6.0 (18.9) 8.7 (23.8) −3.0 (−6.5 to 0.5) 0.088
Hematoma expansion† 76 (27.2%) 89 (34.5%) 0.61 (0.41 to 0.91) 0.015
Day 7, n (%)
Neurological deterioration 127 (40.4) 139 (47.1) 0.71 (0.49 to 1.03) 0.068
Death 53 (16.8) 53 (18.0) 0.81 (0.51 to 1.30) 0.388
DNAR 111 (35.1) 104 (35.3) 0.93 (0.62 to 1.40) 0.726
Day 90
Death, n (%) 110 (34.8) 102 (34.7) 0.89 (0.60 to 1.33) 0.570
mRS >3, n (%) 215 (68.0) 202 (68.7) 0.94 (0.60 to 1.47) 0.782
Barthel index, mean (SD) 37.1 (43.9) 37.9 (44.5) 0.6 (−4.6 to 5.7) 0.828
EQ5D, mean (SD) 0.23 (0.37) 0.23 (0.37) 0.01 (−0.04 to −0.06) 0.758
TICS- M, mean (SD) 7.0 (11.3) 8.0 (12.1) −0.5 (−2.3 to 1.2) 0.550
ZDS, mean (SD) 81.6 (28.4) 81.8 (27.9) −0.6 (−5.1 to 3.9) 0.805
Safety events,‡ n (%)
New stroke 2 (1.0) 2 (1.1) … 1.000
New acute coronary syndrome 0 (0) 1 (0.6) … 0.487
New venous thromboembolism 4 (2.1) 2 (1.1) … 0.686
DNAR indicates do not attempt resuscitation; EQ5D, Euro Quality of Life; NIHSS, National Institutes of Health Stroke Scale; MD, mean difference; mRS, 
modified Rankin Scale; OR, odds ratio; TICS- M, modified telephone interview cognitive status; and ZDS, Zung depression scale.
*Binary logistic regression or multiple linear regression adjusted for age, sex, systolic blood pressure, National Institute of Health Stroke Scale, onset to 
randomization time, intraventricular hemorrhage, and country with addition of baseline hematoma volume for hematoma expansion.
†Hematoma expansion: >6 mL or >33% increase in volume from baseline.
‡Fisher’s exact test.
Figure 1. Functional outcome at day 90 after intracerebral hemorrhage in antiplatelet vs no 
antiplatelet subgroups (adjusted common odds ratio, 1.58; 95% CI 1.32– 1.91; P<0.001).
Analysis was ordinal logistic regression, adjusted for age, sex, systolic blood pressure, National Institutes of Health 
Stroke Scale, onset to randomization time, intraventricular hemorrhage, treatment group, and country.
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antiplatelet- treated patients were more vulnerable to 
fibrinolysis due to disturbance in fibrin formation and 
hence may benefit from tranexamic acid. Other mech-
anisms for the effect of tranexamic acid have been 
proposed such as inhibiting plasmin- induced platelet 
activation but there are conflicting results between 
studies.25– 27 In view of these, the effect of tranexamic 
acid on hematoma expansion in the antiplatelet group 
should be further explored in future studies.
One advantage of the current study is a relatively 
large prospective cohort compared with previous 
studies and an excellent availability of data on func-
tional outcome (99%) and hematoma expansion 
(≈90%). In comparison, many studies that reported on 
relation of pre- ICH antiplatelet therapy with hematoma 
expansion had a significant proportion (30%– 50%) of 
missing follow- up imaging.4,6,28– 31 Therefore, the cur-
rent study is a valuable addition to the literature on 
the effects of antiplatelet therapy in ICH. To the best 
of our knowledge, this study was also the only one to 
evaluate the effects of tranexamic acid on antiplatelet- 
associated ICH.32
Because of the post hoc nature of the analyses, one 
limitation of the study was the findings are mainly hy-
pothesis generating. We endeavored to reduce errors 
caused by multiplicity of testing by adhering to pre-
specified outcome measures and a statistical analysis 
plan. Another limitation was the type and number of 
antiplatelet agents, the duration of treatment, and the 
fact that the last dose was not recorded. Platelet ac-
tivity may be suppressed more significantly in patients 
with dual or triple antiplatelet agents, while some newer 
antiplatelet agents, such as prasugrel or ticagrelor, are 
more potent than older ones, such as clopidogrel or 
aspirin.33 On the other hand, genetic polymorphism 
may lead to reduced efficacy of clopidogrel in some 
patients.34 The degree of platelet inhibition is therefore 
not known. In addition, intensive blood pressure low-
ering in the first 6 hours had been shown to reduce 
hematoma expansion.35 However, blood pressure lev-
els and management within this early window was not 
recorded in our study.
CONCLUSIONS
Pre- ICH antiplatelet therapy is associated with an in-
creased risk of hematoma expansion, neurological de-
terioration, death, and unfavorable functional outcome 
in spontaneous ICH. Trials of hemostatic therapies in 
ICH should include or even prioritize patients with anti-
platelet therapy due to these reasons. Tranexamic acid 
did not have significantly greater benefit in patients 
with antiplatelet- associated ICH, and its use in these 
patients needs to be further explored.
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Figure 2. Effect of tranexamic acid on hematoma expansion, death and death or dependence 
(modified Rankin Scale score [mRS] >3) at day 90 stratified by prior use of antiplatelet therapy.
Analysis was multivariable binary logistic regression with adjustment for age, sex, systolic blood pressure, 
National Institutes of Health Stroke Scale, onset to randomization time, intraventricular hemorrhage, and 
country for outcome of death and mRS >3 at day 90 with additional variable of baseline hematoma 
volume for hematoma expansion. Figure differed from previously published14 as current analysis 
included additional clinical scans; and the presence of intraventricular hemorrhage was based on expert 
radiologists’ adjudication rather than investigator reported. aOR indicates adjusted odds ratio; and mRS, 
modified Rankin Scale.
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